Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andrew Brackmann
WB
Andrew Brackmann
William Blair
Wall Street Analyst
★☆☆☆☆
#2351
on 13Foresight · ranked by our own returns
31%
Success Rate
-7.5%
Average Return
8 of 26 calls profitable · -11.7% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 31% of Andrew Brackmann's ratings turned a profit when each position was held for 1 year — averaging -7.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

86 Buy 46 Hold 0 Sell
Andrew's Stock Coverage 22 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
BFLY
Butterfly Network
 Jun 18, 2026 BUY Strong Buy
-48.9% avg upside
7 analysts
 — ·
ADPT
Adaptive Biotechnologies
 Jun 16, 2026 BUY Strong Buy
+19.9% avg upside
14 analysts
 — ·
DGX
Quest Diagnostics
 Jun 15, 2026 BUY Buy
-12.4% avg upside
33 analysts
 — -2.2%
TEM
Tempus AI, Inc. Class A
 Jun 01, 2026 HOLD Strong Buy
+33.4% avg upside
19 analysts
 — -4.2%
NEO
NeoGenomics
 May 27, 2026 HOLD Strong Buy
+37.2% avg upside
17 analysts
 — +16.5%
GH
Guardant Health
 May 27, 2026 BUY Strong Buy
-5.9% avg upside
30 analysts
 — +1.2%
CDNA
CareDx
 May 27, 2026 HOLD Buy
+25.1% avg upside
16 analysts
 — +4.9%
MDXH
MDxHealth
 May 14, 2026 HOLD Strong Buy
+1073.0% avg upside
8 analysts
 — -44.9%
XGN
Exagen
 May 12, 2026 BUY Strong Buy
+159.4% avg upside
10 analysts
 — -1.9%
NTRA
Natera
 May 08, 2026 BUY Strong Buy
+7.4% avg upside
26 analysts
 — +16.6%
OWLT
Owlet
 May 08, 2026 BUY Strong Buy
+142.2% avg upside
10 analysts
 — -15.8%
BLLN
BillionToOne, Inc. Class A
 May 07, 2026 BUY Strong Buy
+16.4% avg upside
8 analysts
 — +8.8%
SERA
Sera Prognostics
 May 07, 2026 BUY Strong Buy
+325.6% avg upside
7 analysts
 — -8.8%
QDEL
QuidelOrtho
 May 06, 2026 HOLD Buy
+183.5% avg upside
13 analysts
 — +19.8%
VCYT
Veracyte
 May 06, 2026 BUY Strong Buy
-20.7% avg upside
17 analysts
 — -6.6%
BDSX
Biodesix
 May 05, 2026 BUY Strong Buy
+92.3% avg upside
8 analysts
 — -0.9%
LH
Labcorp Holdings
 Apr 30, 2026 BUY Strong Buy
+1.8% avg upside
36 analysts
 — -0.1%
QGEN
Qiagen
 Apr 28, 2026 HOLD Buy
+14.1% avg upside
23 analysts
$38.00
2.81% Upside
 -3.7%
ABT
Abbott Laboratories
 Jan 23, 2026 BUY Strong Buy
+31.2% avg upside
35 analysts
 — -17.1%
BDX
Becton Dickinson
 Aug 08, 2025 HOLD Buy
+35.5% avg upside
25 analysts
 — -3.0%
ALDX
Aldeyra Therapeutics
 Oct 01, 2024 BUY Strong Buy
+713.6% avg upside
21 analysts
 — -0.9%
SGHT
Sight Sciences
 Feb 03, 2022 BUY Buy
+52.9% avg upside
13 analysts
 — -21.2%
🔒 17 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Andrew Brackmann — Frequently Asked Questions
How accurate are Andrew Brackmann's stock ratings?
Based on the calls 13Foresight could measure, about 31% of Andrew's ratings were profitable over a one-year hold, with an average return of -7.5% per rating, or -11.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Andrew ranked on 13Foresight?
Andrew Brackmann is currently ranked #2351 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andrew cover?
Andrew most recently has ratings on BFLY, ADPT, DGX, TEM, NEO, GH, CDNA, MDXH, XGN, NTRA, OWLT, BLLN and 10 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.